People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alcresta Therapeutics, Inc. | — | Biotechnology | Series C | $75.9M | $409.6M | 2016 |
Martin Paz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Paz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Garheng Kong | 1 | 16 |
| James Topper | 1 | 12 |
| Stephen Kraus | 1 | 7 |
| Daniel Tasse | 1 | 4 |
| Todd Creech | 1 | 4 |
| Alexey Margolin | 1 | 3 |
| William Scheinler | 1 | 2 |
| Robert Gallotto | 1 | 2 |
| Steve Dubin | 1 | 1 |
| Jeremy Lack | 1 | 1 |
| Anastasios Konidaris | 1 | 1 |
| Daniel Orlando | 1 | 1 |
| Eric First | 1 | 1 |
| James Gamgort | 1 | 1 |
| Stephen Krauss | 1 | 1 |
| Tasos Konidaris | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.